Copenhagen[®] Snuff Fine Cut

Tobacco Products Scientific Advisory Committee

February 6 & 7, 2019



Introduction

Jose Luis Murillo, J.D.

Senior Vice President, Regulatory Affairs Altria Client Services



Proposed Modified Risk Claim

IF YOU SMOKE, CONSIDER THIS:

Switching completely to this product from cigarettes reduces risk of lung cancer.



WARNING: This product can cause mouth cancer.

Almost Two Centuries in Market

• Copenhagen[®] Snuff Fine Cut has been in market since 1822

IF YOU SMOKE, CONSIDER THIS:

Switching completely to this product from cigarettes reduces risk of lung cancer.



Presents a Dilemma and an Opportunity

IF YOU SMOKE, CONSIDER THIS:

Switching completely to this product from cigarettes reduces risk of lung cancer.



WARNING: This product can cause mouth cancer.

Scientific Evidence Supports Risks Reduction

Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic	The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US	American Journal of Preventive Medicine Volume 33, Issue 6, Bupplement, December 2007, Pages 8375-8386	Health & Consumer Protection	Ь
analysis for the Global Burden of Disease Study 2016	Reduction Group	Article . It	EUROPEAN COMMISSION	٤
GBD 2016 Risk Factors Collaborators*	ABSTRACT in tobacco smoke and oral tobacco and even	Effect of Smokeless Tobacco Product Marketing and Use on		
Summary Background The Global Burden of Diseases. Injuries, and Risk Factors Study 2016 (GBD 2016) provides a	The issues related to take to have reduction continue to making implied or direct claims to reduce the trick lic	Population Harm from Tobacco Use: Policy Perspective for		~
sackground in Giobal Burden of Diseases, injuries, and Rusk factors Study 2016 (GBD 2016) provides a comprehensive assessment of risk factor exposure and attributable burden of disease. By providing estimates over a	challenge the tobacco control research and policy of cancer or other diseases, these products raise			
long time series, this study can monitor risk exposure trends critical to health surveillance and inform policy debates	communities. The potential for combusting tobacco important public health policy questions.	Tobacco-Risk Reduction		
on the importance of addressing risks in context.	products to reduce exposure and risk remains largely The new tobacco products that are being offered as a	5.4	5.3	
Vera vera	unknown, but this has not stopped manufacturers from offering such products making these claims. The role of to burn tobacco, while others employ novel	Lynn T. Kozlowski PhD A B ra	ates	4 H.
Methods We used the comparative risk assessment framework developed for previous iterations of GBD to estimate sates levels and trends in exposure, attributable deaths, and attributable disability-adjusted life-years (DALYs), by age group, later	oral to acco products in a hum reduction regimen has the choice such while others employ nove bates	± 8how more tes	ade to the second se	des a
sex, year, and location for 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks des a	also been a source of dialogue and debate. Within the last blades to burn or heat tobacco. Advertisements for des a	ides a	ov	Ner a
from 1990 to 2016. This study included 481 risk-outcome pairs that met the GBD study criteria for convincing or mate	few years, major cigarette manufacturing companies have a number of novel combustible products promise mate and the second secon	https://doi.org/10.1016/j.amepre.2007.09.015 Get rights and content at ever a	lare eb	bates
probable evidence of causation. We extracted relative risk (RR) and exposure estimates from 22717 randomised outper entry	begun selling smokeless products for the first time, to reduce or eliminate exposue to a subset of roup, daming to tapet current charges unders. Other	up, enaites	Scientific Committee on Emerging and Newly Identified Health Risks	
to the GBD 2016 source counting methods. Using the counterfactual scenario of theoretical minimum risk exposure is or	daiming to target current cigarette smokers. Other cigarette manufacturers are also offering smokdess to second-hand smoke. Increasingly, non-combus-	sks	Scientific committee on Emerging and Newly Identified Health Kisks	imate
level (TMREL), we estimated the portion of deaths and DALYs that could be attributed to a given risk. Finally, we mised	products in markets anound the workd. The harmeduction	Abstract ed timate	sed gr	roup,
explored four drivers of trends in attributable burden: population growth, population ageing, trends in risk exposure, ding friels	debate has at times been divisive. There has been no mines compared with conventional products, are rding reisks	ing roup		risks
and all other factors combined.	unifying set of principles or goals articulated to guide being marketed with promises of tobacco satisfac- wure ing or	This article presents policy perspectives on the marketing of smokeless tobacco products to	SCENIHR	Ag or
Findings Since 1990, exposure increased significantly for 30 risks, did not change significantly for four risks, and	tobacco control efforts. In particular, the research needs tion in situations (eg, at work or at home) where twe mised	reduce population harm from tobacco use. Despite consensus that smokeless tobacco are, and are	SCENTIK III.	rding
decreased significantly for 31 risks. Among risks that are leading causes of burden of disease, child growth failure and	are extraordinarily high in order to drive evidence-based policy in this area and avoid the mistakes made with combust or not, all of these products are appar-		por	osure
household air pollution showed the most significant declines, while metabolic risks, such as body-mass index and high ossure	Tight cigarettes. This paper discusses recommendations entry aim of these products are appar-	products as sold in the United States are less dangerous than cigarettes, there is no source	and By	g, we
fasting plasma glucose, showed significant increases. In 2016, at Level 3 of the hierarchy, the three leading risk factors in terms of attributable DALYs at the global level for men were smoking (124-1 million DALYs 195% UI 111-2 million to asure,	from a strategic dialogue held with key, mostly US-based addicted smokers unable or not wanting to guit, and esure.	consensus on how to proceed. Diverse factions have different policy concerns. While the	and	sure,
in terms of authousable DALIS at the global keys for men were smooting (124-1 million DALIS [95% 01 111-2 million to s and 137, 0 million) high systemic blob blob meressure (122-2 million DALIS [95% 01 111-2 million to be birthweight to a second state of the second	tobacco control researchers and policy makers to develop From a public health perspective, there is concern	tobacco industry is exempted from U.S. Food and Drug Administration (FDA) oversight, the	ligh	
and short gestation (83.0 million DALYs [78.3 million to 87.7 million]), and for women, were high systolic blood	a strategic vision and blueprint for research, policy and about tobacco products bearing unsubstantiated high		lors s.	and
pressure (89-9 million DATYs 180.9 million to 98.2 million), high body mass index 164.8 million DATYs 144.4 million as an and	communications to reduce the harm from tobacco for the claims to reduce exposure and tisk." They have entered	pharmaceutical industry whose nicotine replacement therapy (NRT) medicines compete with Brs s, and	10	e and


among the te leading risk f drivers of cha 9-3% (6-9-1) ageing accou (10-1-14-9) o burden is see 2006 and 201

Smokeless tobacco use presents less risk of lung cancer

		from hundring in Sweden). Nicotre delivey systems of direct visual of the hundred in the second log delatation is stated in the second systems of for public health. Khune myddardy stated in the hundred for public health. Khune myddardy stated in the hundred for public health. Khune myddardy stated in the during myddia hundred in the second second system of the hundred public health by affecting attractiveness and/or toxicity and the line of more digramets in the could imput outlic health by affecting attractiveness and/or toxicity and the line of the second second second second second digramets advances on the second	accowrapped in tolesco leaf, though modern produced products offers employ recon- inel tolesco sheet in wrappers. Subvariate of the second second second second second second reconstruction of the second second second second reconstruction of the second second second second 1990s, particularly among adolescents and 1990s, particularly among adolescents and the second seco	lion lion to in evident inced blood the b		students reported smoking during vehicle	e 19 e 19 e 19 e 19 e 19 e 19 e 19 e 19	 imate imate imate risis imate 	Second Report of a WHO Study Group World Health Organization	imate proposition provides pro		Professor of Health Psychology, University College London hm McNeill Honorary Senior Lecturer, St George's Hospital Medical School Jawn Milner Tobacco Control Consultant http://woodcock Professor of Respiratory Medicine, University of Manchester
			0 1 1 1			issued in 1964, concluded that "the use of tobacco, especially cigarette sm	k-	re and		t d high		
		public nearth by affecting attractiveness and/or toxicity. when	rein the lighted end is placed in the mouth.	ight d high		early warnings, the first U.S. Surgeon General's report on smoking and he iccurated in 1964, concluded that "the use of tobacco, as pagially citarratia cm	lth, n	s, and		re and		
	I			re and		early warnings, the first U.S. Surgeon General's report on smoking and he	alth, o	A and		s, and		
				n to re and						⁶ s, and	1	Konrad Jamrozik
				n to re and						⁶ s, and	1	Konrad Jamrozik
				ight and		early warnings, the first U.S. Surgeon General's report on smoking and he	alth, o	burn a s		s, and		
		public health by affecting attractiveness and/or toxicity. when	rein the lighted end is placed in the mouth.	ight a black		early warnings, the first U.S. Surgeon General's report on smoking and he	alth, m	s and		s, and		
		public nearth by affecting attractiveness and/or toxicity. when	rein the lighted end is placed in the mouth.	ight d high		early warnings, the first U.S. Surgeon General's report on smoking and he	alth, n	s s, and		a and		
		when	tern the agriced end is placed in the modeli.	agnt d high		issued in 1964, concluded that "the use of tobacco, especially cigarette sm	ika li	s, and		e and		Professor of Primary Care Epidemiology, Imperial College of Science.
	I						N-	re and		t d high		
		Cigar	rs and pipes	hon lion to		ing, has been causally linked to several diseases," including lung cancer,	a.	d high		A Factory		Technology and Medicine
				6 in mainht		coronary artery disease, chronic bronchitis, and emphysema.	e	factors				realition by and medicine
include and poor include and an include an include an include and an include and an include and an include an include an include and an include an inclu		cigar	its are traditionally comprised or shreaded	ined 11 at				a lion to		mon to		
Clears an ptradicionally comprised of shreaked in weight coronary attery disease, chronic bronchits, and emphysema.				the			430	1 minutes		weight		Martin Jarvis
Cigan are tradicably comprised of shreaded in a digat coronary attray disease, chronic broachis, and emphysema. I is the shore tradicable of the digat in a digat in a disease		BACKGROUND mass	s-produced products often employ recon-	nilbon				weight		blood		
Cigars are unput of shreaded in wight coronary anter discuss, chronic bronchits, and emphysema. di koros tobacco wapped in tohuco kaf, though moden and historia di tobacco kaf, though moden and hist				016 in		adult population—smoke cigarettes.		blood		nillion		Professor of Health Psychology, University College London
BACKGROUND massprodulationally comprised products of memory merging for the control is and membry service data serv				s an nained		Although this rate is far lower than		nillion		1016 in		
Cigan are tradicably comprised of shrekded in sign comma strey disease, chronic bonchis, and emplycema. is kores backceround tabacco wrapped in toknoco wrappe				tion on the			11	t 016 in		III OIN		Ann McNeill
BACKGROUND Compared trafficionally comprised of shreadsh Single Contraction Single Contraction BACKGROUND Tobacco use is projected to kill things product of the shift is not is for the shift is n		likely he killed by their use of circumster tohooco. (whi	ich often have a filter) to cientilles to large	ASC DE				a stand		ained		Ann MCNelli
Accessence Coars me translowally comprised of shreaking bactors wrapped in tolacco keft hough modern Tolsacco use its projected to kill 1 billion prepare during the latt century. While the majority by arc, from cigramy etc. coronary attery disease, chronic bouchits, and emplyeema. descence descence descence BACKGROUND Tolsacco kee its projected to kill 1 billion prepare descence descence descence descence descence descence Tolsacco kee its projected to kill 1 billion prepare data data descence descence descence descence descence Tolsacco kee its projected to kill 1 billion prepare data data data descence descence descence descence Tolsacco kee its projected to kill 1 billion prepare data data data descence descence descence descence Tolsacco kee its projected to kill 1 billion prepare data data data descence descence descence Tolsacco kee its projected to kill 1 billion prepare data data data data descence descence data Tolsacco kee its projected to kill 1 billion projected to kill billion projected to kill billion data data data data data Tolsacco kee its projected to kill billion projected to kill billion data				1470 portant		decline in smoking among adults 280		sained		as the		Hannahar Cardina Lastrona, Ch.Caranah Hanridal Madical Caland
According to an indicating on privated of shreaded in a stage of shreaded in a stag	I	use in other forms also contributes to worldwide cigare	rs (which themselves vary tremendously). ¹⁰ 11	case ins an				as the		S COL		Honorary Senior Lecturer, St George's Hospital Medical School
BACKGROUND Community with the manyory with the function of the standing of the s				and and and		appears to have leveled off during # 200	Real Provide Re	6 matternal		ortant		
BACKGROUND Community in traditionally computed of shreads in traditionally computed in the computance of the community in traditional program in traditint program in tradition program in tradition program in t		morbidity and mortality." Table 1 lists a selection of Cigar	ir smoking enjoyed resurgence in the US in			much of the part decade Many 200		orunt		ans an		
BACKBROUND Commany attract functionally comprised of shreaded functions benchmark and the state of the		different classes of non-cigarette forms of tobacco the	1990s, particularly among adolescents and	12-4%				ins an		a lation		Dawn Milner
BACKGROUND Community outputed of shread bills BACKGROUND Tobacco usin projected to kill 1 bills projected rot kill 1 bills Community outputed of shread bills Community out		in telefit chines of hore-equierte forms of connects the	believe in the ball believe the			adolescents also are smoking regu-	an 1997	a dation		12 101		
And Markel Construction Con		use, including smoked products, smokeless prod- those	e believing it to be less hazardous than	liscase		larly or are experimenting with to- \$ 120		12.497		2-4%		Tobacco Control Consultant
BACKGROUND Commany attractionally comprised of sheads in the shead provide in tractional component of sheads in the shead provide in tractional component is shead provide in tractional c		ucts and also non-tobacco delivery of nicotine ² cisare	rettes 9 12-16 The use of cigars and wranners	stween				LZ-4%		isease		
B Computed of shrekdally shrekdally computed of shrekdally computed	I	acts and may non-contects derivery of incounter. Cigar	renear the use of eights and whappens	sure			10	isease	(d)	2		
Image: Construct training on project of the short form also constructions to weak book to garst training on project of the short form also constructions to weak book to be the short form also constructions to weak book to weak		Such products have historically been treated (blun	nts) to administer marijuana and other drugs	n to		13 nament of middle school stu	9 14 30 80	C Decorr		sween		
Image: Construct training on project of the short form also constructions to weak book to garst training on project of the short form also constructions to weak book to be the short form also constructions to weak book to weak		differently from cigarettes for tax and regulatory also	has generated concern 17-20 Pines are tradi-	ent i				e				Ashley Woodcock
Image: Construct training on project of the short form also constructions to weak book to garst training on project of the short form also constructions to weak book to be the short form also constructions to weak book to weak		date entry from eigneeds for the first regulatory and	ing generated concern. Tipes are trained	acome			kide Dove Saikide Smeking		Stars Billion	P		
Image: Construct training on project of the short form also constructions to weak book to garst training on project of the short form also constructions to weak book to be the short form also constructions to weak book to weak	I	purposes, and often have longer histories of use tional	ally composed of a bowl (made of clay or other	vely posure		students reported smoking during	kille brug Sucine Smoking	5		tromo		Professor of Respiratory Medicine, University of Manchester
BACKGROUD Communication of the second se		than manufactured cigarettes. All forms of tobacco non-c	combustible materiall where the tobacco is	diam to be			in occes at	frome	E organization	a contract		
Amount of the second of the				non to		the preceding month—a troubling Comparative causes of annual deaths in the	United States, SOURCE; CDC.	r and and a		posure		
Sectors 01 Construction 10 Const		use have negative health consequences, though the place	ed for burning, attached to a stem through	ment.				posure		tion to		
And the products of the second part of			the emoke is drawn. The tobaccos used in	atively				tion to		and the second		Additional background information was supplied by Professor Geraint Howells
And the products of the second part of								tracent		success.		autonal oucaground mornauon nus supplied by frotesor Geraint fromeis
A matching Comparison Comparison <td></td>												
According in the set in the set is defined to the set is defined to interpose of the set i		tially among products. ¹ There is evidence that some pipes	s may sometimes be flavoured. Data on char-									
According in the set in the set is defined to the set is defined to interpose of the set i		tially among products. ¹ There is evidence that some pipes	s may sometimes be flavoured. Data on char-	e.				atively				
According Construction Co		tially among products. ¹ There is evidence that some pipes	s may sometimes be flavoured. Data on char-	е.				atively	A CONTRACT OF AUDITAL FURNING OF ENVIRENCES IN A 20 OPTI ACCESS TO REPORT OF CC. II 1 50 DOM			
According Construction Co	ļ	tially among products. ¹ There is evidence that some pipes	s may sometimes be flavoured. Data on char-	e	Cor	pyright © The Author(s), Published by Elsevier Ltd. This is an Open Access art	icle under the CC BY 4.0 license.	atively	copyright 83 The Authority, Fuorented by Ebevier Ed. This is an open Access arises unser the CC B1 4.9 methods		6	povright @ The Author(s). Published by Elsevier I.d. This is an Open Access article under the CC BY
ACCORDING Consider training only consider products of the end by only used, found, modely many divides consider products of the end by only used, found, modely many divides consider products of the end by only used, found, modely many divides constraint training and divides and divide and	ļ	tially among products. ¹ There is evidence that some pipes tobacco and nicotine products may pose less of acteri	s may sometimes be flavoured. Data on char- ristics on ciears and pipes are less commonly	e.	Cop	pyright @ The Author(s). Published by Elsevier Ltd. This is an Open Access art	icle under the CC BY 4.0 license.	atively	сорунция до тик лишилця, гионанного у каж на тик и ин орен лессяя вниж шине ние селот вля испо		G	pyright @ The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY
ACCORDING Consider training only consider products of the end by only used, found, modely many divides consider products of the end by only used, found, modely many divides consider products of the end by only used, found, modely many divides constraint training and divides and divide and	ļ	tially among products. ¹ There is evidence that some pipes tobacco and nicotine products may pose less of acteri	s may sometimes be flavoured. Data on char- ristics on ciears and pipes are less commonly	e.	Cop	pyright @ The Author(s). Published by Elsevier Ltd. This is an Open Access art	cle under the CC BY 4.0 license.	atively	сарунун ау так лаваацуу таканаа ау тактат как так и же орен лесси жеке шкат час ос ит са изга		G	pyright @ The Author(s). Published by Elsevier Idd. This is an Open Access article under the CC BY
According Construction Co	ļ	tially among products. ¹ There is evidence that some pipes tobacco and nicotine products may pose less of acteri	s may sometimes be flavoured. Data on char- ristics on ciears and pipes are less commonly	e.	Cop	pyright © The Author(s). Published by Elsevier Ltd. This is an Open Access art	cle under the CC BY 4.0 license.	atively	oppright Q. The Authority. Function of the test that the time is an open access more most the Oc at a synamic		G	pyright \otimes The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY
ACCORDING Consider training only consider products of the end by only the difficult of gains the solution difficult of gains difficult of gains	ļ	tially among products. ¹ There is evidence that some pipes tobacco and nicotine products may pose less of acteri	s may sometimes be flavoured. Data on char- ristics on ciears and pipes are less commonly	e.	Cop	pyright @ The Author(s). Published by Elsevier Ltd. This is an Open Access art	icle under the CC BY 4.0 license.	atively	copyright () the numerical resonance of sector tax, that is an Open Access and se under the CC HT of sector copyright () the Author(). Pethenical by theorem (al. that is an Open Access and se under the CC HT of	.0 Beense.	6	pyright () The Author(s). Published by Elsevier I.H. This is an Open Access article under the CC BY
ACCORDING Consider training only consider products of the end by only used, found, modely many divides consider products of the end by only used, found, modely many divides consider products of the end by only used, found, modely many divides constraint training and divides and divide and		tially among products. ¹ There is evidence that some pipes tobacco and nicotine products may pose less of acteri	s may sometimes be flavoured. Data on char- ristics on ciears and pipes are less commonly	e.	Cop	pyright () The Author(a). Published by Elsevier Lid. This is an Open Access art Copyright () The Author(a). Published by Elsevier Lid. This is an Open A	cle under the CC BY 4.0 license. cess article under the CC BY 4.0 is	atively	Copyright (g. The Animately), future in a star for the first open access which under the effect of the animately (c. In the animately open access which under the effect of the Animately Statement DA. This is an Upen Access which under the effect of the	e.	G	pyright () The Author(d). Published by Elsevier I.d. This is an Open Access article under the CC BY
ACCORDING Consider training only consider products of the end by only used, found, modely many divides consider products of the end by only used, found, modely many divides consider products of the end by only used, found, modely many divides constraint training and divides and divide and	ļ	tially among products. ¹ There is evidence that some pipes tobacco and nicotine products may pose less of acteri	s may sometimes be flavoured. Data on char- ristics on ciears and pipes are less commonly	e.	Cop	pytight @ The Author(s). Published by Elsevier I.d. This is an Open Access an	cle under the CC BY 4.0 license.	atively icense.	Оруляри су-тие лизакир и такания бу листит сие, так и каторит лесси жиле вале на сости с листи не Соруляри су-тие лизакир лизакие про листит сие так организация и про листи и про листи и сости с листи на Соруляри су-тие лизакир лизакие про листит сие так про листи и про листи и про листи и про листи и сости с ли с	.0 Beense.	G	pyright () The Author(c). Published by Elsevier Lid. This is an Open Access article under the CC BY
ACCORDING Consider training only consider products of the end by only used, found, modely many divides consider products of the end by only used, found, modely many divides consider products of the end by only used, found, modely many divides constraint training and divides and divide and	ļ	tially among products. ¹ There is evidence that some pipes tobacco and nicotine products may pose less of acteri	s may sometimes be flavoured. Data on char- ristics on ciears and pipes are less commonly	e.	Cop	pyright © The Author(4). Published by Elsevier Lid. This is an Open Access an Copyright © The Author(9). Published by Elsevier Lid. This is an Open A	icle under the CC BY 4.0 license.	atively icense.	ору нус у тислинанир гисника кулисти систии и исорегисска висс нами на состо с тисли на состо с тисли нами и со сорунарт (у тислинанир), на какатор, на какатор и законе изд. Тика и до Орен Ассена алка и имает the OC III 4	.0 Beense.	G	pyright © The Author(s). Published by Elsevier Ial. This is an Open Access article under the CC BY Copyright © The Author(s). Published by Elsevier Ial. This is an Open Access article under the
ACCORDING Consider training only consider products of the end by only used, found, modely many divides consider products of the end by only used, found, modely many divides consider products of the end by only used, found, modely many divides constraint training and divides and divide and		tially among products. ¹ There is evidence that some pipes tobacco and nicotine products may pose less of acteri	s may sometimes be flavoured. Data on char- ristics on ciears and pipes are less commonly	e.	Cor	eyright () The Author(s): Published by Elsevier Ltd. This is an Open Access at Copyright () The Author(s): Published by Elsevier Ltd. This is an Open A	cle under the CC BY 4.0 license.	atively icense.	oppright ig: the Animalpi extension by careful par, the transformation and the under the CC or examine Coppright ig: the Animalpi Published by Converting The Unit of all Open Access after a under the CC DT 4	.0 Beense.	6	egright © The Author(s). Published by Elsevier Ial. This is an Open Access article under the CC BY Copyright © The Author(s). Published by Elsevier Ial. This is an Open Access article under the
Sector Construct		tially among products. ¹ There is evidence that some pipes tobacco and nicotine products may pose less of acteri	s may sometimes be flavoured. Data on char- ristics on ciears and pipes are less commonly	e.	Cop	pytight () The Author(s): Published by Elsevier Lid. This is an Open Access at Copyright () The Author(s): Published by klaevier Lid.: This is an Open A	cle under the CC BY 4.0 license.	atively icense.	Oppropring: The Antonique Following of Sherner Use. The Institute Oper Action while while the CC HT COMMUNIC Copyright Q: The Antonique Palanteed by Elsevier EM. This is an Open Access article under the CC HT 4	.0 Bornse.	0	pyright () The Author(s). Published by Ilsevier I.d. This is an Open Access article under the CC BY Copyright () The Author(s). Published by Elsevier I.d. This is an Open Access article under the

Adult Smokers Don't Understand the Relative Risk of Smokeless Tobacco Products

 <u>More than 90%</u> in FDA's PATH survey say that smokeless tobacco products are just <u>as harmful</u> or <u>more harmful</u> than cigarettes




The Opportunity

- Providing accurate information to Adult Smokers results in a net benefit to the population as a whole, including users and nonusers
- The real-world impact could be much larger with sustained exposure over time




Adult Dual Users Present Logical Harm Reduction Opportunity



Based on ALCS analysis of PATH Wave 1 data Sep 12, 2013 - Dec 14, 2014.

Cigarette smokers include those who report having smoked at least 100 cigarettes in their lifetime and now smoking every day or some days. Smokeless Tobacco users include those who report having used ST at least 20 times in their lifetime and now using ST every day or some days.

Over Half of All Adult Smokers Are Interested in Reduced-Risk Tobacco Products



Based on ALCS analysis of PATH Wave 1 data Sept 12, 2013 – Dec 14, 2014; Response to question – "If a tobacco product made a claim that it was less harmful to health than other tobacco products, how likely would you be to use that product?" Numbers may not foot due to rounding.

MRTPA Addresses Statutory Requirements (§911(g)(1))

- The candidate product, as it is actually used by consumers, will:
 - A. Significantly reduce harm and the risk of tobacco-related disease to individual tobacco users; and
 - B. Benefit the health of the population as a whole taking into account both users of tobacco products and persons who do not currently use tobacco products.

Consumer Communications Standard

- The information provided to consumers must be:
 - Accurate
 - Not misleading
 - Supported by scientific evidence

Agenda

Jose Luis Murillo, J.D. Senior Vice President, Regulatory Affairs Altria Client Services	Introduction
Mohamadi Sarkar, M. Pharm, Ph.D., FCCP	
Fellow, Regulatory Affairs Altria Client Services	Scientific Evidence
Gary Harvey	
Vice President and Principal Consultant William E. Wecker Associates, Inc	Health Risk
Stephanie Plunkett, Ph.D.	
Senior Director, Perception and Behavior Research Altria Client Services	Claim Development and Testing
Ryan Black, Ph.D.	
Director, Regulatory Affairs Altria Client Services	Population Impact
Jose Luis Murillo, J.D.	
Senior Vice President, Regulatory Affairs Altria Client Services	Conclusion

Claim Complements Public Health Prevention and Cessation Strategies

Under FDA oversight, informing adult smokers about reduced-risk products will *complement*, *not compete* with, proven public health strategies focused on prevention and cessation

IF YOU SMOKE, CONSIDER THIS:

Switching completely to this product from cigarettes reduces risk of lung cancer.



FDA Recognition of Continuum of Risk

Dr. Scott Gottlieb FDA Commissioner

"[W]e must acknowledge that there's a continuum of risk for nicotine delivery. That continuum ranges from combustible cigarettes at one end, to medicinal nicotine products at the other."

"[W]e must also take a new and fresh look at the noncombustible side."

"[P]olicies should account for changes that will move addicted smokers down that continuum of risk to...less harmful products."

Combustibles	Non-Combustibles	Medicinal Nicotine
Highest Risk	(Directional: Not to scale)	Lowest Risk cc-⁄

Proposed Claim



Claim is for Adult Smokers

Adult Never-Users and Adult Smokers Planning to Quit did not show increased interest in the product

IF YOU SMOKE, CONSIDER THIS:

Switching completely to this product from cigarettes reduces risk of lung cancer.



Claim is for Adult Smokers

- Correcting misperceptions will take time
- Comprehensive campaign directed to adult smokers



Claim is for Adult Smokers

- Correcting misperceptions will take time
- Comprehensive campaign directed to adult smokers
 - Print advertising
 - Direct mail
 - Copenhagen[®] branded website

IF YOU SMOKE, CONSIDER THIS:

Switching completely to this product from cigarettes reduces risk of lung cancer.



Consumer Communications

Print Advertisements

Accompanied by the required rotational warnings

Limited to publications that meet the criteria of an "adult publication" under FDA's definition

Federally Mandated Warnings

WARNING: This product can cause mouth cancer.

WARNING: This product can cause gum disease and tooth loss.

WARNING: This product is not a safe alternative to cigarettes.

WARNING: Smokeless tobacco is addictive.

Consumer Communications

Print Advertisements

Accompanied by the required rotational warnings

Limited to publications that meet the criteria of an "adult publication" under FDA's definition **Direct Communications**

- We verify consumers' age *and*
- Certify that they are smokers and/or smokeless tobacco users before they can receive the communications

UST Trade Programs and Youth Access Prevention

- Limit display of products to non-self-serve locations
- Train store personnel who sell tobacco products using We Card[®] or equivalent training
- Place retail signage that prohibits underage sales and tells adults not to buy tobacco products for underage use



Long History of Product Use



Description of Copenhagen[®] Snuff

- Blend of 100% American-grown tobacco
- Water
- Salts
- Flavors



Copenhagen[®] Snuff Use Patterns



- "Pinch" between lip and gum for ~ 30-40 minutes
- Average consumption about one half of a can per day

Copenhagen[®] Snuff Consumers



• Consumers of Copenhagen[®] Snuff are, by and large:

- Adult white males
- 35 years of age and older

Overview of Support for Authorization of Claim

- Claim is supported by the scientific evidence
- Meets statutory standard for a claim
- Represents an important first step towards solving the dilemma faced by adult smokers

Authorizing the Proposed Claim

- Provides adult smokers a <u>reason</u> to switch
- Offers facts to make an informed decision



Switching completely to this product from cigarettes reduces risk of lung cancer.



Scientific Evidence

Mohamadi Sarkar, M. Pharm, Ph.D., FCCP

Fellow, Regulatory Affairs Altria Client Services



Comprehensive Scientific Review

~6,500 publications

	Global regional, and national comparative risk assessment of B4 behavious d, environmental and occupational, and metabolic tricks colorism of risks, 2009-2016 o systematic analysis for the Global Burden of Disease Study 2016	Global, regional, and national comparative risk assessment
	Global, regional, and national comparative risk assessment of 4 & Hehavioural, environmental and occopational, and metabolic risks or dotters of risks, 1996-2016, a system analysis for the Global Rivelen of Disease Study 2016 metabolic risks of the Hehavioural, environmental and occopational metabolic risks of the Hehavioural, environmental and occopational metabolic risks of the Hehavioural environmental and occopational metabolic risks of other Study 2016 a system metabolic risks of other Study 2016 a system	of B4 behavioural, environmental and occupational, and metabolic risks or donesters of risks. 1990-02016: a systematic analysis for the Global Burden of Disease Study 2016 "In the second advance" "The second advance" of the second advance of
	Summer Operation Operating of the horizontal and thehorizontal and thehorizontal and thehorizontal andin hor	A set of the second set of the second set of the second second second set of the second secon
\mathbf{A}	Analysis for the Gobal Borden of Despace Study 2016 and analysis for the Gobal Borden	An interpretation of the second se
		/
	Global, regional, and national comparative risk assessment of Babahavooral, reminensement and ecospatismal, and metabolic risks or closers of risks, 1939-3036 a systematic analysis in the distribution of research procession bases of Babahavooral.	L and national comparative risk sussement og anvennemmalt and ecopations. And e otheres of risks. 1209-030% a up treasuate
	Non-cigarette tobacco products: where an ad comparative risk assessment in kinema and where are we headed? Non-cigarette tobacco products: whet have we learn and where are we headed? Inter all comparative risk assessment water and to be assessment of the second secon	An UNATION THINKS & PROFENSIONAL AND
	Implementation Amount Margin Amount	maked a star and with the field of address of the star and the star an
		/
	Fold-ML regional, and national regional participation with answer search of the the investment and comparison and and comparison of the methods, the last of search and the search of the search of the search of the search of the search of the search of the search of the search of the methods are search of the	_ /
	The second se	en en el contra de la contra
	~1,000	
	publicatio	ns

Literature Review Protocol included inclusion/exclusion criteria based on published best practices¹


	Original research, including secondary analyses and meta-analyses
Inclusion	Reports from authoritative bodies (e.g., U.S. Surgeon General, IARC, etc.)
	Studies of smokeless tobacco products sold in the U.S.
	Published in the English language
	Studies of smokeless tobacco products sold in other countries than the U.S.
Exclusion	Studies of non-U.S. populations (e.g., Swedish snus epidemiology)
	Published in a foreign language

1. IOM Report "Finding What Works in Health Care: Standards for Systematic Reviews" (IOM, 2011), the Cochrane Handbook for Systematic Reviews of Interventions (Cochrane Collaboration, 2011), and the PRISMA Statement (Moher et al., 2009).


Review Covered Diverse Array of Health Topics

- Epidemiology
- Clinical
- Nonclinical
 - Tobacco or tobacco extracts
 - Specific tobacco constituents

Applicability of Epidemiology




Moist Smokeless Tobacco Was the Predominant Form During Epidemiology Studies



Unit volume of moist smokeless tobacco and loose leaf chewing tobacco derived from Maxwell Reports 1972-2011 CPS-II = Cancer Prevention Study – II; NHEFS = NHANES-I Epidemiologic Follow-up Study Black boxes represent the baseline periods for studies and black circles represent the end of follow-up period


Moist Smokeless Tobacco Was the Predominant Form During Epidemiology Studies



Unit volume of moist smokeless tobacco and loose leaf chewing tobacco derived from Maxwell Reports 1972-2011


NHIS = National Health Interview Survey; NLMS = National Longitudinal Mortality Study; CPS-II = Cancer Prevention Study – II; NHEFS = NHANES-I Epidemiologic Follow-up Study Black boxes represent the baseline periods for studies and black circles represent the end of follow-up period

Copenhagen[®] Snuff Was One of the Major Products Consumed During Epidemiology Studies



Unit volume of moist smokeless tobacco and loose leaf chewing tobacco derived from Maxwell Reports 1972-2011; UST volumes based on historical shipment data NHIS = National Health Interview Survey; NLMS = National Longitudinal Mortality Study; CPS-II = Cancer Prevention Study – II; NHEFS = NHANES-I Epidemiologic Follow-up Study Black boxes represent the baseline periods for studies and black circles represent the end of follow-up period

Multiple Lines of Evidence



Smokeless Tobacco is Less Hazardous than Cigarettes – *Public Health Consensus*

"On the continuum of risk, non-combustible tobacco products are more likely to reduce harm than a smoked form of tobacco for individuals who would otherwise be using conventional cigarettes."

Source: Zeller, Hatsukami *et al., The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US.* Tobacco Control, 18(4), 324-332, 2009

"Spit or smokeless tobacco is a less lethal, but still unsafe, alternative to smoking."

Source: American Cancer Society Website. "Health Risks of Smokeless Tobacco" (Last accessed Feb. 4, 2019)

"[U]sers of smokeless tobacco products generally have lower risks for tobacco-related morbidity and mortality than users of combustible tobacco products such as cigarettes."

Source: WHO Study Group on Tobacco Product Regulation (TobReg), The Scientific Basis of Tobacco Product Regulation, 951 WHO Technical Reports Series (2008)

Health Risk of Copenhagen[®] Snuff

Gary Harvey

Vice President and Principal Consultant William E. Wecker Associates, Inc.



Key Questions


- Do smokeless tobacco users have the same or lower <u>lung</u> <u>cancer</u> risks compared to current smokers?
- Do smokeless tobacco users have the same or lower <u>all-cause</u> and <u>all-cancer</u> mortality risks compared to current smokers?


Linked Mortality Analysis: Based on Nationally Representative Epidemiology


SUPERIOR S	IONAL ALTH RVIEW RVEY ce 1957		Census Bureau	
National Health Interview Survey		National Longitudinal Mortality Study Based on the Current Population Survey		
1987 – 2005 (intermittent)	•	Survey Years	→ 1993 – 2005	
154,391	•	Total Respondents	→ 210,090	
3,006	•	Smokeless Tobacco Users	→ 3,492	


Two nationally representative public health surveys linked to the National Death Index (2011 update)*

*Mortality outcomes available through linkage to the National Death Index (NDI) available from the National Center for Health Statistics Third party trademarks, logos, images and other artwork are the property of their respective owners, are used for reference only, and are not intended to suggest any affiliation.











Andreotti 2016 and Wynder 1977 included mortality and lung cancer "incidence".




Andreotti 2016 and Wynder 1977 included mortality and lung cancer "incidence".

Lung Cancer Mortality Risks Among Former Smokers




CC-46

All-Cause Mortality Risks




All-Cause Mortality Risks




Linked Mortality Sensitivity Analyses

- Men and women
- All races and white only
- Other causes of death beyond lung cancer, all-cause, and all-cancer
- Alternative model specifications and control variables
- None of these sensitivity analyses importantly impacted the conclusions


All-Cause Mortality Risks



All-Cancer Mortality Risks



All-Cancer Mortality



Andreotti 2016 includes "Cancer incidence", Lee 2009 includes "death" and "incidence".

Key Takeaways – Health Risk

- Smoking cigarettes dramatically increases the risks of lung cancer, all-cause mortality and all-cancer
- If current smokers quit smoking, then their risks are dramatically reduced
- Smokeless tobacco users' risk of lung cancer is statistically significantly lower than that of current smokers

Copenhagen[®] Snuff Claim Development and Testing

Stephanie Plunkett, Ph.D.

Senior Director, Perception and Behavior Research Altria Client Services



Presentation Overview

- Behavioral theory
- Claim development and testing
- Claim comprehension and risk perception findings
- Impact of the claim on behavioral intentions

Presents a Dilemma and an Opportunity

IF YOU SMOKE, CONSIDER THIS:

Switching completely to this product from cigarettes reduces risk of lung cancer.




WARNING: This product can cause mouth cancer.

Presentation Overview

Behavioral theory


- Claim development and testing
- Claim comprehension and risk perception findings
- Impact of the claim on behavioral intentions

Ajzen's Theory of Planned Behavior



Adapted from Ajzen, 1985; Godin & Kok, 1996

Applied Theory of Planned Behavior and Switching



Misperceptions of Smokeless Tobacco Health Risk Published Literature

Borland et al. Harm Reduction Journal 2012, 9 :19 http://www.harmreductionjournal.com/content/9/1/19		Borland et al. Harm Reduction Journal 2011, 8:21 http://www.harmreductionjournal.com/content/8/1/21	HARM REDUCTION	Nicotine & Tobacco Research Volume 9, Number 9 (September 2007) 977–982 headthcare
RESEARCH	Open Access	RESEARCH	Open Access	Brief report
Effects of a Fact Sheet on b harmfulness of alternative n	icotine delivery	Trends in beliefs about th of stop-smoking medication		Harm perception of nicotine products in college freshmen
systems compared with ciga	arettes	tobacco products among	cigarettes smokers:	Stephanie Y. Smith, Barbara Curbow, Frances A. Stillman
Ron Borland ^{1,8*} , Lin Li ¹ , K Michael Cummings ² , Richard O'Conno Lars Ramstrom ⁶ , Bill King ¹ and Ann McNeill ^{4,7}	³ , Kevin Mortimer ⁴ , Tom Wikmans ⁵ ,	Findings from the ITC fou	ir-country survey	Received 9 February 2006; accepted 9 October 2006
Abstract		Ron Borland ^{1*} , Jae Cooper ¹ , Ann McNeill ² , Richard O'Conno	or ³ and K Michael Cummings ³	This study examined the association of sociodemographic characteristics and smoking behaviors (i.e., cigarette, cigar, and waterpipe) with nicotine product harm perception in college freshmen. Students were asked to compare the perceived harmfulness of 11 nicotine-delivering products with that of a regular cigarette. Data were from a 9

Communicating accurate risk information is key

versus combustible forms of nicotine delivery.	and the US, where smokeless tobacco is marketed, only	r around one in six believed some smokeless tobacco The current marketplace off	the promotion of a "harm reducing" nicotine
nor the microlune. Some forms of shokeless tobacco (s1) are less harmful than others [1,2], with some existing smokeless products sull very harmful (albeit less harmful than smokeless products sull or al lobacco products used in the 90–95 microlube even less harmful [5], be even less harmful [5], be even less harmful [5], be even less harmful [6], be even less harmful [7], and storage process. However, the used long term [4] be even less harmful [6], be even less harmful [7], and storage process. However, the used long term [4] be even less harmful [7], be even less harmful [7], and storage process. However, the used long term [4] be even less harmful [7], and the difference i of the attributed risk for as it now appears that the risk [9,10]. If a seems public however, harmful storage and the latter of the attributed risk for as the now appears that the most public hower for the attributed risk for as the now appears that the most public hower for the attributed risk for as the now appears that the most public hower for the attributed risk for as the now appears that the most public hower harmful storage harmful harmful attributed risk for as the now appears that the most public hower harmful storage harmful ha	Original Article Evaluation of modified risk claim advertising formats for Camel Snus SeGE	Micotine & Tobacco Research Volume 9, Number 10 (October 2007) 1033-1042 informa Notesting Smokers' beliefs about the relative safety of other tobacco products: Findings from the ITC Collaboration	ed and smokeless idant product mar- dharm' may incite For the smoker a tet may be used to reduct si influenced by perceptions of the product's duct is influenced by perceptions of the product's duct is influenced by perceptions of the product's act may be used to combination with or ine products, with s Robert Wood Johanos Primetron, NY, Barbara Primetron, NY, Barbara Primetron, NY, Barbara Primetron, NY, Barbara (McGuire, 1972). Totacci interpretation and the percent of the product is a s Robert Wood Johanos Primetron, NY, Barbara (McGuire, 1972). Totacci interpretation and the percent of the product is a product that affect their decision-making process (McGuire, 1972). Totacci interpretation and the percent of the product is a product that affect their decision-making process (McGuire, 1972).
	Brian V Fix ^a , Sarah E Adkison ^a , Richard J O'Connor ^a , Maansi Bansal-Travers ^a , K Michael Cummings ^b , Vaughan W Rees ^a and Dorothy K Hatsukami ¹ d ¹⁰ Department of Healto Bahavora, Rowen Plark Career Institute, Bifdio, NY, USA ¹⁰ Department of Pydiatry and Bahavora Siencer, Medica Ulweritory South Carolina, Claurieton, SC, USA ¹⁰ Department of Pydiatry and University of Minesola, Minesplai, RN, USA ¹⁰ Department of Pydiatry, University of Minesola, Minesplai, RN, USA	Richard J. O'Connor, Ann McNeill, Ron Borland, David Hammond, Bill King, Christian Boudreau, K. Michael Cummings Received 19 May 2006; accepted 26 November 2006	BD.5. M.F.H., Forgram aged 18–24 years constitute the largest segment of targeted tobacco marketing efforts (Katz & Lavack, eli (12) 59-0685; Rai: auil.chop.edu Glantz, 2002a. 2002b; Sepe. Ling, & Glantz, 2002b; Sepe. Ling, & dilations between c 2007 Society for Research en Nicoline and Tobacco
BioMed Central ^{2012 Boldmed nd nd, knowne Bolded Central LM his is an Open Access and is dia commons Antibiation. Lenver Holden Central LM his is an Open Access and is dia commons Antibiation. Lenver Holden Central LM his is an Open Access and is dia commons Antibiation. Lenver Holden Central LM his is an Open Access and is dia commons Antibiation. Lenver Holden Central LM his is an Open Access and is dia commons Antibiation. Lenver Holden Central LM his is an Open Access and is dia commons Antibiation. Lenver Holden Central LM his is an Open Access and is dia commons Antibiation. Lenver Holden Central LM his is an Open Access and is dia commons Antibiation. Lenver Holden Central LM his is an Open Access and is dia commons Antibiation. Lenver Holden Central LM his is an Open Access and is dia commons Antibiation. Lenver Holden Central LM his is an Open Access and is dia commons Antibiation. Lenver Holden Central LM his is an Open Access and is dia commons Antibiation. Lenver Holden Central LM his is an Open Access and is dia commons Antibiation. Lenver Holden Central LM his is an Open Access and is dia commons Antibiation. Lenver Holden Central LM his is an Open Access and is dia commons Antibiation. Lenver Holden Access and is dia commons Access and is dis dia commons Access and is dia commons}	Abstract Objectives: The US Food and Drug Administration (FDA) has regulatory authority for modified risk tobacco product adversing claims. To guide future regulatory efforts, we investigated how variations in modified risk claim advertisements influence consume perceptions of product risk dams for Camel Suus. Methods: Young people and adults (15-65), including current, never, and former smokers, were randomised to view noe for Scamel Sung trint advertisements as pair of a web-based survey. Four of the advertisements presented information related to nitroamine content of suus using four formats: (1) text, (2) a bar chart, (3) a textestionnial and (4) a bar christestimonial. The fifth formac, used as a control, was a current advertisement for Camel Suus without the explicit claims made about nitroamine content. After viewing advertisements for all products, participants were asked which product they would be most interested in trying.	Most tobacco control efforts in western countries focus on the factory-made, mass-produced (FM) eigaretic, whereas other tobacco products receive relatively little attention. Noncombusted tobacco products (i.e., referred to as smokeless tobacco), particularly "Sworidi-style smass, carry lower disease risks, compared with combusted tobacco products such as eigarettes. In this context, it is important to know what tobacco users believe about the relative harmfulness of various types of tobacco products. Data for this study cane from random-digit-fielded tekphone surveys of current smokers aged 18 or other in Australia, Canada, the United Kingdom, and the United States. Three waves of data, totaling 13:222 individuals, were assessed. Item as assessed use of and beliefs about the relative harms of eigars, pipes, smokless tobacco, and FM and roll-your-own eigarettes, as well as sociodemographics and moking behaviors. Cigars (28 ²⁴ -127 ³⁵) over the horter boacco products most commonly used by current eigarette smokers, followed by pipes (0.3 ³⁷⁶ -21 ³⁶) and smokeless tobacco (0.0 ⁴⁷⁶ -23 ³⁶), A significant minority of mokers (12 ³⁶ -21 ³⁷) used roll-vour-own eigarettes at least some of the time. About one- quarter of smokers believed that pipes, eigars, or roll-your-own day retardons than eigarettes. Multivariate analyses showed that use of other tobacco products was low but may be growing anolers in the four of these other products. Use of other tobacco products also but may the growing anolers in the four due to be products.	

countries studied. Smokers are confused about the relative harms of tobacco products. Health education efforts ar

needed to correct smoker misnercentions.

Results: Participants exposed to advertisements that contained an explicit reduced risk message agreed

the advertising claim for that product posed fewer health risks than cigarettes. However, advertisements

containing the reduced risk messages were also viewed as containing less truthful information and respondent-

Presentation Overview

Behavioral theory

Claim development and testing

- Claim comprehension and risk perception findings
- Impact of the claim on behavioral intentions

Claim Development Process and CCI Study Design

Phase 1 Modified Risk Claim DEVELOPMENT

DEVELOPMENT of Promotional Material

Round 1

Qualitative study to develop proposed claim

Round 2

Qualitative study to further develop proposed claim

Claim Requirements

- Communicated that consumers knew they needed to stop smoking in order to reduce lung cancer risk
- Consumers understood that there is risk with the use of Copenhagen[®] Snuff

Claim Development Process and CCI Study Design

Phase 1 Modified Risk Claim DEVELOPMENT

DEVELOPMENT of Promotional Material

Round 1

Qualitative study to develop proposed claim

Round 2

Qualitative study to further develop proposed claim

Phase 2 Modified Risk Claim TESTING

TESTING of Promotional Material

CCI Study

Quantitative study to assess the comprehension and the effect of the claim on behavioral intentions

Claim Development Process and CCI Study Design

Phase 2 Key Questions

- Do participants correctly understand the claim?
- Do participants understand that using Copenhagen[®] Snuff still poses a health risk?
- Do participants change their behavioral intentions?

Phase 2 Modified Risk Claim TESTING

TESTING of Promotional Material


CCI Study

Quantitative study to assess the comprehension and the effect of the claim on behavioral intentions


CCI Study Overview

- Quasi-randomized, controlled study design
- 5,871 adult tobacco users and non-users from across the U.S.
- Participants matched to the U.S. population using major demographic variables based on PATH study quotas
- Oversampled legal age to 24-year-old population

CCI Study Subgroups



CCI Study Design




Presentation Overview

- Behavioral theory
- Claim development and testing
- Claim comprehension and risk perception findings
- Impact of the claim on behavioral intentions

Based only on the information shown in this ad, smokers who switch completely from cigarettes to Copenhagen[®] Snuff:

- □ Increase the risk of lung cancer
- □ Reduce the risk of lung cancer
- **□** Eliminate the risk of lung cancer
- Do not know

Participants Comprehend the Claim




Based only on the information shown in this ad, smokers who switch completely from cigarettes to Copenhagen[®] Snuff: Increase the risk of lung cancer, Reduce the risk of lung cancer, Eliminate the risk of lung cancer, Do not know.

General Harm Question

How harmful do you think using Copenhagen[®] Snuff is to a person's health?

- Very harmful
- Moderately harmful
- □ Not at all harmful

Participants Understand Copenhagen[®] Snuff is Not Risk-Free



How harmful do you think using Copenhagen® Snuff is to a person's health? – Not at all harmful, Moderately harmful, Very harmful

General and Specific Diseases Risk Question

How likely is it that these things will happen to a person who only uses Copenhagen[®] Snuff daily?

0% Extremely Unlikely to 100% Extremely Likely


- Negatively impacts health
- Mouth cancer
- □ Hearth disease/heart attack

□ Lung cancer

□ Nicotine addiction

□ Discolored teeth or decay

Likelihood of Health Risks




We realize you may not know the answer to each question, but please give your best answer.

Looking at the same list, how likely is it that these things will happen to a person who only uses Copenhagen® Snuff daily?

0% Extremely Unlikely 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Extremely Likely.

Likelihood of Health Risks



We realize you may not know the answer to each question, but please give your best answer.

Looking at the same list, how likely is it that these things will happen to a person who only uses Copenhagen® Snuff daily?

0% Extremely Unlikely 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Extremely Likely.

Proposed Modified Risk Claim


IF YOU SMOKE, CONSIDER THIS:

Switching completely to this product from cigarettes reduces risk of lung cancer.



WARNING: This product can cause mouth cancer.

Likelihood of Lung Cancer (Test) Copenhagen[®] Snuff vs. Smoking Cigarettes




Key Takeaways – Comprehension and Perceptions

- Tobacco users and non-users correctly understand the claim
- After viewing the claim, users and non-users continue to believe Copenhagen[®] Snuff poses risk to health
- The claim shows potential to help correct misperceptions of lung cancer risk in Adult Smokers Not Planning to Quit


Presentation Overview

- Behavioral theory
- Claim development and testing
- Claim comprehension and risk perception findings
- Impact of the claim on behavioral intentions

CCI Study Design



Behavioral Intentions Assessed



Intention to Use Measure



I would consider using Copenhagen[®] Snuff more than once.

I expect to use Copenhagen[®] Snuff.


It is likely that I will regularly use Copenhagen[®] Snuff in the next 6 months.

Copenhagen[®] Snuff will be my regular brand of dip/snuff in the next 30 days.


Behavioral Intentions Results

- Significant difference in Intention to Use among Adult Smokers Not Planning to Quit
- No other significant differences in behavioral intentions were observed

Likelihood of Behavior Measure



Likelihood of Behavior Metric



and

Intention to purchase right now (Yes/No scale)

Relative Impact

Adult Tobacco Use Behavior	Change in Likelihood of Behavior* (Relative Impact Factor)
Cigarette Smokers Switching to Copenhagen [®] Snuff	1.21
Cigarette Smokers Transitioning to Dual Use	1.16
Dual Users Switching to Copenhagen [®] Snuff	1.06
Former Smokeless Tobacco Users Relapsing to Copenhagen [®] Snuff	1.00
Never Users Initiating with Copenhagen [®] Snuff	0.80

Key Takeaways

- Consumers understand that using Copenhagen[®] Snuff poses risks to health and are not misled
- Data indicate a favorable response to the claim
- It will take time and repeated reinforcement of this message for adult smokers to switch completely to Copenhagen[®] Snuff

Population Impact

Ryan Black, Ph.D.

Director, Regulatory Affairs Altria Client Services



Presentation Overview

- Gateway
- Youth use
- Population modeling
- Postmarket surveillance

Presentation Overview

Gateway


- Youth use
- Population modeling
- Postmarket surveillance

Gateway Effect


 Concern that individuals who do not already use tobacco will start using a less hazardous tobacco product, like Copenhagen[®] Snuff, and switch to a more harmful tobacco product, like cigarettes



Claim Did Not Increase Likelihood of Use Adult Never Users



Claim Did Not Increase Likelihood of Use Adult Never Users Legal Age to 24



Presentation Overview

- Gateway
- Youth use
- Population modeling
- Postmarket surveillance




Youth should not use <u>any</u> tobacco product. Reduced-risk messages should not influence youth to use Copenhagen[®] Snuff or any other tobacco product.

Understanding Youth Use

- Relied on publically available resources including:
 - Government data
 - National Survey on Drug Use and Health
 - Monitoring the Future
 - FDA's PATH Study
 - Published literature


Prevalence of Youth ST Use Stable to Declining

Percentages Reporting Past 30-Day Smokeless Tobacco Use by Age Group (NSDUH)



As represented by the dotted line, smokeless tobacco use question modified with the inclusion of snus in the definition of smokeless tobacco in 2015. Adapted from National Survey on Drug Use and Health Behavioral Health Trends Report (2015), Detailed Tables (2016-18)

Youth Use of Copenhagen[®] Snuff is Very Low



Exposure To Claim Did Not Impact Youth Susceptibility To Use (EI-Toukhy et al., 2018)

 480 youth (13-17 year olds) randomized to receive one message by risk claim and by product type

Risk Claim

- Less harmful than cigarettes
- As harmful as cigarettes, or
- No statement (control)

Product Type

- Heat-not-burn
- E-vapor
- Snus

 Researchers found that the lower risk claim had no effect on susceptibility to use among youth

Presentation Overview

- Gateway
- Youth use
- Population modeling
- Postmarket surveillance

- Predict outcomes within a population under changing dynamics
- Rely in part on empirical data in addition to estimates and assumptions, informed by evidence
- Shed light on trends, not intended to predict future outcomes with numerical precision

Model Validation

Developed and validated the cohort model

- Used best practices as described by
 - Institute of Medicine (IOM)
 - International Society of Pharmacoeconomics and Outcomes Research (ISPOR)
 - Society for Medical Decision Making (SMDM)

Modeling the Impact on the Population


Linked MortalityCCI StudyRisk of using
smokeless tobacco relative
to cigarette smokingChanges in product use
patterns due to the modified
risk claimImage: Study of the study of th

Model Inputs

- Male population defined by the U.S. Census data
- Tobacco use patterns informed by systematic literature review published by public health scientists including FDA research scientists
- Risk of exclusive smokeless tobacco use relative to cigarette smoking estimated from the Linked Mortality Analyses


Modeling Framework: Multiple Cohort Approach

Base Case – World As Is Today




Modeling Framework: Multiple Cohort Approach

Base Case – World As Is Today



Modified Case – Future World



Blue Arrows = Modified Transitions

Adult Male Transition Rates

Tobacco Use Transition	Base Case Transitions* (From the Literature)	Modified Case Transitions* (Adjusted from CCI Study)
1 Current smoker → ST	1.4%	1.7%
Current smoker → Dual user (ST + cigarettes)	3.2%	4.0%
3 Dual user → ST	17.4%	18.4%
4 Former ST \rightarrow ST	1.8%	1.8%
5 Never user → ST	1.6%	1.5%

*Five year transition rates


Adult Male Transition Rates

Tobacco Use Transition	Base Case Transitions* (From the Literature)	Modified Case Transitions* (Adjusted from CCI Study)
Ourrent smoker → ST	1.4%	1.7%
2 Current smoker → Dual user (ST + cigarettes)	3.2%	4.0%
3 Dual user \rightarrow ST	17.4%	18.4%
4 Former ST → ST	1.8%	1.8%
5 Never user \rightarrow ST	1.6%	1.5%


*Five year transition rates

Modeling Framework: Multiple Cohort Approach

Base Case – World As Is Today



Modified Case – Future World




Blue Arrows = Modified Transitions

Base case transition rates largely informed by Tam J., Day H.R., Rostron B.L., Apelberg B.J. A systematic review of transitions between cigarette and smokeless tobacco product use in the United States. BMC Public Health. 2015;15:258

Modeling Framework: Multiple Cohort Approach

Base Case – World As Is Today




Modified Case – Future World

Approximately 93,000 premature deaths prevented over the 60 years following claim authorization

Robust Findings from Sensitivity Analyses

• Concurrently vary:

- Change in rate of Never Tobacco Users initiating on smokeless tobacco (Initiation)
- Change in rate of Cigarette Smokers switching to smokeless tobacco (Switching)
- All other transition rates kept the same as those in the Modified Case scenario



Presentation Overview

- Gateway
- Youth use
- Population modeling
- Postmarket surveillance

- Postmarket studies (e.g., crosssectional and longitudinal cohort studies)
 - Transitions among tobacco users
 - Initiation/cessation
 - Risk perceptions
 - Awareness of modified risk communication

- Postmarket studies (e.g., crosssectional and longitudinal cohort studies)
 - Transitions among tobacco users
 - Initiation/cessation
 - Risk perceptions
 - Awareness of modified risk communication
- Refining population modeling input parameters

- Postmarket studies (e.g., crosssectional and longitudinal cohort studies)
 - Transitions among tobacco users
 - Initiation/cessation
 - Risk perceptions
 - Awareness of modified risk communication
- Refining population modeling input parameters

- Adverse event reporting
 - Consumer Response Center
 - Clinical studies
 - Literature reviews
 - FDA Adverse Events Reporting System/ Health and Human Services Safety Portal

- Postmarket studies (e.g., crosssectional and longitudinal cohort studies)
 - Transitions among tobacco users
 - Initiation/cessation
 - Risk perceptions
 - Awareness of modified risk communication
- Refining population modeling input parameters

- Adverse event reporting
 - Consumer Response Center
 - Clinical studies
 - Literature reviews
 - FDA Adverse Events Reporting System/ Health and Human Services Safety Portal
- Literature reviews
 - Health effects
 - Risk perceptions
 - Patterns of use
 - Misuse/abuse/tampering

- Postmarket studies (e.g., crosssectional and longitudinal cohort studies)
 - Transitions among tobacco users
 - Initiation/cessation
 - Risk perceptions
 - Awareness of modified risk communication
- Refining population modeling input parameters

- Adverse event reporting
 - Consumer Response Center
 - Clinical studies
 - Literature reviews
 - FDA Adverse Events Reporting System/ Health and Human Services Safety Portal
- Literature reviews
 - Health effects
 - Risk perceptions
 - Patterns of use
 - Misuse/abuse/tampering
- Monitoring and secondary analyses of national survey data

Conclusion

Jose Luis Murillo, J.D.

Senior Vice President, Regulatory Affairs Altria Client Services



Copenhagen[®] Snuff MRTPA Summary

- Proposed claim is truthful, accurate and substantiated by scientific evidence
- Copenhagen[®] Snuff is significantly less harmful than cigarettes
- Switching completely from cigarettes to Copenhagen[®] Snuff reduces the risk of lung cancer
- Tobacco users and non-users understand Copenhagen[®] Snuff is not risk-free
- Population benefit is expected with authorization of the claim

Presents a Dilemma and an Opportunity


IF YOU SMOKE, CONSIDER THIS:

Switching completely to this product from cigarettes reduces risk of lung cancer.



WARNING: This product can cause mouth cancer.

Over Half of All Adult Smokers Are Interested in Reduced-Risk Tobacco Products



Based on ALCS analysis of PATH Wave 1 data Sept 12, 2013 – Dec 14, 2014; Response to question – "If a tobacco product made a claim that it was less harmful to health than other tobacco products, how likely would you be to use that product?" Numbers may not foot due to rounding.

Proposed Claim Can Begin Correcting Misperceptions

IF YOU SMOKE, CONSIDER THIS:

Switching completely to this product from cigarettes reduces risk of lung cancer.



WARNING: This product can cause mouth cancer.

Additional Experts Available for Questions

Michael Fisher, Ph.D.	Senior Principal Scientist Altria Client Services
Simeon Chow, Ph.D.	Vice President Altria Client Services
Kenya Blake	Senior Director U.S. Smokeless Tobacco Co.
Yezdi Pithawalla, Ph.D.	Senior Director Altria Client Services
Ed Largo, Ph.D.	Director Altria Client Services
Tim Danielson, Ph.D.	Senior Principal Scientist Altria Client Services

Copenhagen® Snuff Fine Cut

Tobacco Products Scientific Advisory Committee

February 6 & 7, 2019




Applicant Backup Slides Shown

Tobacco Products Scientific Advisory Committee

February 6 & 7, 2019



Intention to Use Copenhagen[®] Snuff Adult Tobacco Users




I would consider using Copenhagen® Snuff more than once. I expect to use Copenhagen® Snuff. It is likely that I will regularly use Copenhagen® Snuff in the next 6 months. Copenhagen® Snuff will be my regular brand of snuff/dip/smokeless tobacco in the next 30 days. 6=Strongly Agree, 5=Agree, 4=Somewhat Agree, 3=Somewhat Disagree, 2=Disagree, 1=Strongly Disagree. Composite Score calculated by averaging across the four measures, at the individual level.

*Statistically significant difference between test and control (ANCOVA)

Likelihood Behavior Measures - ASNPQ

Test - Pre Test - Post




Intention to Use, Switch & Dual Use Copenhagen[®] Snuff Table of P-Values

	ASPQ	ASNPQ	Dual Users	MST Users	Former Users	Never Users	Tobacco Users LA-24	Tobacco Non-Users LA-24
Intention to use	0.133	0.002	0.742	0.460	0.243	0.149	0.803	0.533
Intention to switch	0.553	0.049	0.281	-	-	-	0.972	-
Intention to dual use	0.635	0.109	0.563	-	-	-	0.789	-

Copenhagen[®] Snuff is Relevant to Adult Smokers

Copenhagen[®] Snuff Users



• Among the 460K Copenhagen[®] Snuff users:

- 380K were exclusive users
 - -140K were former adult smokers*
- ▶ 80K were dual users

Based on ALCS analysis of PATH Wave 1 data Sep 12, 2013 – Dec 14, 2014.


Cigarette smokers include those who report having smoked at least 100 cigarettes in their lifetime and now smoking every day or some days. Smokeless Tobacco users include those who report having used ST at least 20 times in their lifetime and now using ST every day or some days. *Former Smokers are defined as having smoked 100+ cigarettes but not currently smoking every day or some days.

Believability by Incoming Beliefs on Lung Cancer

• The majority (68%) of respondents who did not find the ad believable came in perceiving the risk of lung cancer from using Copenhagen® Snuff to be 100% (Extremely Likely)

		Соре	Copenhagen Snuff: Lung Cancer Risk (Pre) and Ad Believability Cross tabulation										
		0% Extremely Unlikely %	10% %	20% %	30% %	40% %	50% %	60% %	70% %	80% %	90% %	100% Extremely Likely %	/ Total
	Strongly Disagree	7.3%	2.0%	2.2%	1.8%	5.0%	8.1%	5.6%	4.2%	7.5%	8.3%	48.0%	N=496
	Disagree	5.0%	4.4%	3.3%	6.8%	8.3%	13.6%	7.1%	8.6%	9.8%	10.9%	22.2%	N=338
Q164. This ad is believable	Neither Agree Nor Disagree	10.1%	5.9%	7.3%	5.7%	8.3%	15.6%	7.4%	7.7%	6.3%	5.7%	20.1%	N=795
	Agree	13.7%	12.5%	8.7%	9.2%	6.7%	13.6%	6.0%	7.7%	6.1%	5.5%	10.2%	N=963
	Strongly Agree	21.7%	9.1%	6.5%	4.1%	2.3%	9.1%	3.8%	5.6%	5.9%	8.5%	23.5%	N=341
Total													N=2933

Oral Cancer Mortality Risks Smokeless Tobacco Risk Ratios




HPHC Data vs STP Category – TSNAs

	Copenhagen [®] Snuff Mean (± 95% CI)	2014-2015 MST Market Survey Mean Range (min - max)	2014 MST Market Survey Copenhagen [®] Snuff Mean	2015 MST Market Survey Copenhagen [®] Snuff Mean
TSNAs		ng/grar	n (as-is)	
ΝΝΚ	472 (88.3)	97 - 1751	831	381
NNN	1746 (73.8)	552 - 5222	2403	1523

Copenhagen[®] Snuff Data Source: Section 7.1, N= 35 replicates (5 lots each with 7 replicates) Market Survey 2014-2015 Data Source: https://digitalmedia.hhs.gov/tobacco/static/mrtpa/RJR/6_RESEARCH/5%20Section%206.1.5%20-%20Chemistry_Redacted.pdf Market surveys to determine the HPHC content of U.S. smokeless tobacco products were conducted in 2014 and 2015 Twenty-two moist snuff products were sampled in 2014 representing a total of 68% of the moist snuff market share. Twenty-nine moist snuff products were sampled in 2015 representing a total of 72% of the moist snuff market share.

Past 30-Day Smokeless Tobacco Use Among Youth NSDUH, YRBS, MTF



Year


National Survey on Drug Use and Health (NSDUH): <u>https://www.samhsa.gov/data/report/2017-nsduh-annual-national-report</u>

Note: For smokeless tobacco, 2015 and prior years' data are not comparable due to methodological changes in 2015 - snus combined into measure.

Youth Risk Behavior Survey (YRBS): https://www.cdc.gov/healthyyouth/data/yrbs/pdf/2017/ss6708.pdf

Note: For smokeless tobacco, 2017 and prior years' data are not comparable due to methodological changes in 2017. Beginning in 2017 snus and dissolvable tobacco were combined into the smokeless measure. Monitoring the Future (MTF): <u>http://monitoringthefuture.org/data/18data/18data/18drtbl7.pdf</u>


Past 30-Day Smokeless Tobacco Use Among Middle School and High School Students (NYTS)



https://www.cdc.gov/mmwr/volumes/67/wr/mm6722a3.htm


2015 and prior years data are not comparable due to changes in reporting in 2015. In 2015 smokeless tobacco includes chewing tobacco/snuff/dip, snus, and dissolvable tobacco. Prior to 2015, smokeless tobacco included only chewing tobacco/snuff/dip.

All-Cancer Mortality Risks From Smokeless Tobacco and Snuff




Andreotti 2016 includes "Cancer incidence".


Diseases of the Heart Mortality Risks




Round 2 Specific Language Exploration




Mortality Risks Among Current Smokers Lung Cancer, All-Cancer and All Causes in NHIS and NLMS



Mortality Risks Among Former Smokers Lung Cancer, All-Cancer and All Causes in NHIS and NLMS



Lung Cancer Mortality Risks




HR-27

Results: Time-staggered Multiple Cohort


Age Group (y)	Mean Premature Deaths Prevented (Base Case)	Mean Premature Deaths Prevented (Modified Case)	Difference in Premature Deaths Prevented in the Year 2075 (Modified - Base)
0-4 (2075)	11,659,500	11,659,500	0
5-9 (2070)	11,503,227	11,503,227	0
10-14 (2065)	11,343,808	11,343,808	0
15-19 (2060)	11,384,863	11,384,863	0
20-24 (2055)	11,210,354	11,210,354	0
25-29 (2050)	10,975,342	10,975,495	153
30-34 (2045)	10,691,192	10,691,665	473
35-39 (2040)	10,397,394	10,398,367	973
40-44 (2035)	10,099,412	10,101,332	1,920
45-49 (2030)	9,783,564	9,787,295	3,731
50-54 (2025)	9,348,637	9,355,425	6,788
55-59 (2020)	8,747,530	8,757,301	9,771
60-64 (2015)	8,038,615	8,050,922	12,307
65-69 (2010)	7,676,364	7,691,177	14,813
70-74 (2005)	6,873,894	6,889,508	15,614
75-79 (2000)	5,759,539	5,774,009	14,470
80-84 (1995)	4,749,605	4,761,915	12,310
Total Premature Deaths Prevented in the Base vs. Modified Case	160,242,840	160,336,163	93,323

Time-staggered Multiple Cohort Approach

By the end of the follow-up



Risk Perceptions – Populations of Interest



We realize you may not know the answer to each question, but please give your best answer. Looking at the same list, how likely is it that these things will happen to a person who only uses Copenhagen® Snuff daily? 0% Extremely Unlikely 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Extremely Likely.

Would-be Quitter to ST Sensitivity Analysis (Not Modified by CCIS)

Transition Rate, %	Difference in Premature Deaths Prevented
0	94,680
5 (Modified Case)	93,323
10	91,966
20	89,251
50	81,109
100	67,539